Enliven Therapeutics Inc
ELVN
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.65B
Close$
$1.74
96.6% downside
Current Fair Value
96.6% downsideOvervalued by 96.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.65 Billion |
|---|---|
| Enterprise Value | $3.52 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.83 |
| Beta | 0.26 |
| Outstanding Shares | 62,799,326 |
Return
| Return on Equity | -21.79% |
|---|---|
| Return on Assets | -21.25% |
| Return on Invested Capital | -24.45% |
Valuation & Multiples
| P/E Ratio | -31.15 |
|---|---|
| PEG | 180.85 |
| Price to Sales | - |
| Price to Book Ratio | 7.39 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -31.74 |
| Enterprise Value to Net Income | -36 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 20, 2026
EPS Estimate
$-0.44
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 31.83% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.63%▼ 109.47% |
|---|---|
| Total Invested | $20.10M▼ 99.17% |
| Investors Holding | 8▼ 172.00% |
ESG Score
No data
About Enliven Therapeutics Inc
41 employees